ReviewWorld journal of gastroenterology2021
Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?
Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
The Influence of Secretin Stimulated Pancreatic Secretion on Circulating Tumor DNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
Who cites it
67 citing papers in PubMed, 111 citations in OpenAlex.
- miRNA484 and miRNA335-5p as Potential Diagnostic Biomarkers for CA19-9-Negative Pancreatic Ductal Adenocarcinoma.Biomolecules · 2026Article
- New-Onset Diabetes and Pancreatic Ductal Adenocarcinoma: Implications for Early Recognition and Clinical Management.Diabetes/metabolism research and reviews · 2026Review
- Diabetes mellitus, ABO Blood groups, and biochemical correlates in pancreatic cancer- A retrospective study from Jeddah.Journal of family medicine and primary care · 2026Article
- Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer.Discover oncology · 2026Review
- The Critical Role of GALNTs-Regulated O-GalNAc Glycosylation in Cancer Malignancy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Alpha-Fetoprotein Is a Potential Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC): A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- <p>Unveiling sex differences in pancreatic ductal adenocarcinoma: Current evidence and future directions (Review)</p>.International journal of oncology · 2026Review
- Article
- Supramolecular PDDA/PEDOT:PSS Biosensor for Early Pancreatic Cancer Detection via CA19-9: Clinical Validation on Human Blood Samples.ACS omega · 2026Article
- Research progress on early diagnostic markers for pancreatic cancer.World journal of surgical oncology · 2026Review
- Association of HPGDS Expression with Prognosis and Immune Microenvironment Remodeling in Pancreatic Cancer.Cancer management and research · 2026Article
- Soluble CTLA-4 and high-risk genetic variants: A new frontier in pancreatic ductal adenocarcinoma (PDAC) biomarkers.Biochemistry and biophysics reports · 2025Article
- Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2025Article
- Bridging diabetes and cancer: harnessing biomarkers as dual sentinels for diagnosis, prognosis, and therapeutic advancements.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Point-of-Care Testing and Biomarkers in Biliary Diseases: Current Evidence and Future Directions.Journal of clinical medicine · 2025Review
- Article
- Pancreatic Stone Protein as a Versatile Biomarker: Current Evidence and Clinical Applications.Diseases (Basel, Switzerland) · 2025Review
- The role of visfatin and omentin-1 gene polymorphism in pancreatic ductal adenocarcinoma (PDAC).Molecular biology reports · 2025Article
- Review
- Targeting early diagnosis and treatment of pancreatic cancer among the diabetic population: a comprehensive review of biomarker screening strategies.Diabetology & metabolic syndrome · 2025Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a leading cause of cancer related mortality on a global scale. The disease itself is associated with a dismal prognosis, partly due to its silent nature resulting in patients presenting with advanced disease at the time of diagnosis. To combat this, there has been an explosion in the last decade of potential candidate biomarkers in the research setting in the hope that a diagnostic biomarker may provide a glimmer of hope in what is otherwise quite a substantial clinical dilemma. Currently, serum carbohydrate antigen 19-9 is utilized in the diagnostic work-up of patients diagnosed with PC however this biomarker lacks the sensitivity and specificity associated with a gold-standard marker. In the search for a biomarker that is both sensitive and specific for the diagnosis of PC, there has been a paradigm shift towards a focus on liquid biopsy and the use of diagnostic panels which has subsequently proved to have efficacy in the diagnosis of PC. Currently, promising developments in the field of early detection on PC using diagnostic biomarkers include the detection of microRNA (miRNA) in serum and circulating tumour cells. Both these modalities, although in their infancy and yet to be widely accepted into routine clinical practice, possess merit in the early detection of PC. We reviewed over 300 biomarkers with the aim to provide an in-depth summary of the current state-of-play regarding diagnostic biomarkers in PC (serum, urinary, salivary, faecal, pancreatic juice and biliary fluid).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.